Conference
5-factor prognostic model for survival of patients with metastatic urothelial carcinoma receiving three different post-platinum PD-L1 inhibitors.
Abstract
4552
Background: A prognostic model for overall survival (OS) of metastatic urothelial carcinoma (mUC) was previously reported in the setting of post-platinum atezolizumab (Pond GR, GU ASCO 2018). This model was limited by employing only atezolizumab treated patients (pts), small size of the validation dataset and unclear applicability to other PD-1/L1 inhibitors. Hence, we constructed a robust prognostic model utilizing the …
Authors
Sonpavde G; Manitz J; Gao C; Hennessy D; Makari D; Niegisch G; Rosenberg JE; Bajorin DF; Grivas P; Apolo AB
Volume
37
Pagination
pp. 4552-4552
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2019
DOI
10.1200/jco.2019.37.15_suppl.4552
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X